Johnson & Johnson has shifted its generative AI strategy away from broad experimentation across the healthcare conglomerate to a more focused approach. Chief Information Officer Jim Swanson said ...

Ph.D., Global Therapeutic Area Head, Oncology, Johnson & Johnson Innovative Medicine. "TAR-200 provides a new approach, with clinical data showing an impressive complete response rate ...

He said it was to show respect. Advertisement “I think it’s big for me to just come in and be able to shake guys’ hands, see them in person,” Johnson said Tuesday. “I just talked to them ...